Liquidia Tech Drug Patent Portfolio
Liquidia Tech owns 1 orange book drug protected by 6 US patents Given below is the list of Liquidia Tech's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10898494 | Dry powder treprostinil for the treatment of pulmonary hypertension | 05 May, 2037 | Active |
| US11660304 | Dry powder treprostinil for the treatment of pulmonary hypertension | 05 May, 2037 | Active |
| US11712442 | Dry powder treprostinil for the treatment of pulmonary hypertension | 05 May, 2037 | Active |
| US11744835 | Dry powder treprostinil for the treatment of pulmonary hypertension | 05 May, 2037 | Active |
| US11744836 | Dry powder treprostinil for the treatment of pulmonary hypertension | 05 May, 2037 | Active |
| US12390475 | Dry Powder Treprostinil For The Treatment Of Pulmonary Hypertension | 05 May, 2037 | Active |
Latest Legal Activities on Liquidia Tech's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Liquidia Tech.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 26 Aug, 2025 | US12390475 |
| Email Notification | 19 Aug, 2025 | US12390475 |
| Patent Issue Date Used in PTA Calculation | 19 Aug, 2025 | US12390475 |
| Mail Patent eGrant Notification | 19 Aug, 2025 | US12390475 |
| Patent eGrant Notification | 19 Aug, 2025 | US12390475 |
| Recordation of Patent eGrant | 19 Aug, 2025 | US12390475 |
| Email Notification | 07 Aug, 2025 | US12390475 |
| Issue Notification Mailed | 06 Aug, 2025 | US12390475 |
| Application Is Considered Ready for Issue | 04 Aug, 2025 | US12390475 |
| Dispatch to FDC | 04 Aug, 2025 | US12390475 |
| Issue Fee Payment Received | 08 Jul, 2025 | US12390475 |
| Issue Fee Payment Verified | 08 Jul, 2025 | US12390475 |
| Printer Rush- No mailing | 30 Apr, 2025 | US12390475 |
| Information Disclosure Statement considered | 30 Apr, 2025 | US12390475 |
| Pubs Case Remand to TC | 15 Apr, 2025 | US12390475 |
Liquidia Tech's Family Patents
Clinical Trials
Recent Clinical Trials by Liquidia Tech:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD | Liquidia Technologies, Inc. | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks | Liquidia Technologies, Inc. | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE2 |
Liquidia Tech Drug List
Given below is the complete list of Liquidia Tech's drugs and the patents protecting them.
1. Yutrepia
Yutrepia is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10898494 | Dry powder treprostinil for the treatment of pulmonary hypertension |
05 May, 2037
(10 years from now)
| Active |
| US11660304 | Dry powder treprostinil for the treatment of pulmonary hypertension |
05 May, 2037
(10 years from now)
| Active |
| US11712442 | Dry powder treprostinil for the treatment of pulmonary hypertension |
05 May, 2037
(10 years from now)
| Active |
| US11744835 | Dry powder treprostinil for the treatment of pulmonary hypertension |
05 May, 2037
(10 years from now)
| Active |
| US11744836 | Dry powder treprostinil for the treatment of pulmonary hypertension |
05 May, 2037
(10 years from now)
| Active |
| US12390475 | Dry Powder Treprostinil For The Treatment Of Pulmonary Hypertension |
05 May, 2037
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yutrepia's drug page